Caroline M.P.W. Mandigers

Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial

Mette S. van Ramshorst, Anna van der Voort, Erik van Werkhoven et al. · The Lancet Oncology · 2018 · 413 citations · Full text

Breast Oncology, Oncology, Dual Her2 Blockade +7

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis

Linda M. Henricks, Carin A.T.C. Lunenburg, Femke M. de Man et al. · The Lancet Oncology · 2018 · 403 citations · Full text

Medicine, Prospective Safety Analysis, Cancer Management +9

Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

Michèle Cavo, Francesca Gay, Meral Beksaç et al. · The Lancet Haematology · 2020 · 377 citations · Full text

Hematological Malignancy, Transplantation, Marrow Transplantation +9

Upfront Genotyping of <i>DPYD</i>*<i>2A</i> to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis

Maarten J. Deenen, Didier Meulendijks, Annemieke Cats et al. · Journal of Clinical Oncology · 2015 · 333 citations · Full text

A Novel Method to Compensate for Different Amplification Efficiencies between Patient DNA Samples in Quantitative Real-Time PCR

Jules P.P. Meijerink, Caroline M.P.W. Mandigers, Louis van de Locht et al. · Journal of Molecular Diagnostics · 2001 · 306 citations · Full text

Engineering, Measurement, Dna Analysis +17